Prolactin response to nemonapride, a new antipsychotic drug, in schizophrenic patients

Human Psychopharmacology

Volumn 12, Issue 6, 1997, Pages 591-594

  Otani, K ^a,d   Kondo, T ^a   Yasui, N ^a   Suzuki, A ^a   Furukori, H ^a   Kaneko, S ^a   Ohkubo, T ^a   Nagasaki, T ^b   Sugawara, K ^a   Hayashi, K ^c  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b Goshogawara City Hospital   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d YAMAGATA UNIVERSITY   (Japan)

Author keywords

D2 receptor; Nemonapride; Prolactin; Schizophrenia

Indexed keywords

BENZAMIDE; BIPERIDEN; CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EMONAPRIDE; FLUNITRAZEPAM; HALOPERIDOL; NEUROLEPTIC AGENT; PROLACTIN; SULPIRIDE; ZOTEPINE;

ADULT; ARTICLE; CATATONIA; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; FEMALE; GENDER; HUMAN; MALE; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE;

EID: 6844266273     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199711/12)12:6<591::AID-HUP926>3.0.CO;2-U     Document Type: Article

References (15)

1. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, revised, (DSM-III-R). American Psychiatric Association, Washington, DC.
2. Harnryd, C., Bjerkenstedt, L., Gullberg, B., Oxenstierna, G., Sedvall, G. and Wiesel, F-A. (1984). Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatrica Scandinavica, 69 (Suppl. 311), 75-92.
3. King, D. J., Devaney, N., Cooper, S. J., Blomqvist, M. and Mitchell, M. J. (1990). Pharmacokinetics and antipsychotic effect of remoxipride in chronic schizophrenic patients. Journal of Psychopharmacology, 4, 83-89.
4. Linkowski, P., Hubain, P., von Frenckell, R. and Mendlewicz, J. (1984). Haloperidol plasma levels and clinical response in paranoid schizophrenics. European Archives of Psychiatry and Neurological Sciences, 234, 231-236.
5. Meltzer, H. Y., Busch, D. A. and Fang, V. S. (1983b). Serum neuroleptic levels in schizophrenic patients and clinical response. Psychiatry Research, 9, 271-283.
6. Meltzer, H. Y., Goode, D. J., Schyve, P. M., Young, M. and Fang, V. S. (1979). Effect of clozapine on human serum prolactin levels. American Journal of Psychiatry, 136, 1550-1555.
7. Meltzer, H. Y., Mikuni, K., Simonovic, M. and Gudelsky, G. A. (1983a). Effect of a novel benzamide, YM-09151-2, on serum prolactin levels. Life Sciences, 32, 1015-1021.
8. Mori, A., Kazamatsuri, H., Kaneko, S., Kamijima, K., Kariya, T., Murasaki, M. and Yagi, G. (1989). A double-blind comparison of a new benzamide compound YM-09151 with haloperidol in the treatment of schizophrenia. Clinical Evaluation, 17, 349-377 (in Japanese).
9. Otani, K., Kondo, T., Ishida, M., Sasa, H., Higuchi, H., Kaneko, S. and Fukushima, Y. (1993). Prolactin response to zotepine in schizophrenic patients. Human Psychopharmacology, 8, 35-39.
10. Otani, K., Kondo, T., Kaneko, S., Ishida, M. and Fukushima, Y. (1994). Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients. International Clinical Psychopharmacology, 9, 287-289.
11. Rubin, R. T. (1987). Prolactin and schizophrenia. In: Psychopharmacology: The Third Generation of Progress, Meltzer, H. Y. (Ed.), Raven Press, New York, pp. 803-808.
12. 2-dopaminergic receptors. Japanese Journal of Pharmacology, 33, 749-755.
13. 3H] raclopride for dopamine D-2 receptor binding to rat striatum. European Journal of Pharmacology, 173, 177-182.
14. Usuda, S., Nishikori, K., Noshiro, O. and Maeno, H. (1981). Neuroleptic properties of cis-N-(-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4- methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity. Psychopharmacology, 73, 103-109.
15. Van Putten, T., Marder, S. R. and Mintz, J. (1991). Serum prolactin as a correlate of clinical response to haloperidol. Journal of Clinical Psychopharmacology, 11, 357-361.